Overview

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Status:
Withdrawn

Trial end date:
2019-11-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of itacitinib in participants with moderate to severe ulcerative colitis (UC).

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation